Asieris Presents for the First Time Interim Analysis Data of

Asieris Presents for the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU

SHANGHAI, Jan. 29, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering,

Related Keywords

United States , Shanghai , China , Thailand , American , Linda Wu , Alfred Witjes , Asieris Pharmaceuticals Stock Code , Asieris Pharmaceuticals , Stock Code , Clinical Oncology Genitourinary Cancers Symposium , Chief Development Officer , Clin Oncol , Thailand Business ,